This Post Was Syndicated Under License Via QuoteMedia
NEW YORK, NY / ACCESSWIRE / October 11, 2019 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit. If you suffered a loss, you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.
Meredith Corporation (NYSE:MDP)
Class Period: January 31, 2018 to September 5, 2019
Lead Plaintiff Deadline: November 5, 2019
According to the complaint, Meredith Corporation allegedly made materially false and/or misleading statements and/or failed to disclose that: (1) the Time, Inc. acquisition was not as profitable as the Company had claimed; (2) the Company would incur additional costs for strategic investments to improve the Time business; (3) as a result, the Company’s earnings would be materially and adversely impacted; and (4) as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects, were materially misleading and/or lacked a reasonable basis.
Learn about your recoverable losses in MDP: http://www.kleinstocklaw.com/pslra-1/meredith-corporation-loss-submission-form?id=3909&from=1.
Myriad Genetics, Inc. (NASDAQ:MYGN)
Class Period: September 2, 2016 to August 13, 2019
Lead Plaintiff Deadline: November 26, 2019
During the class period, Myriad Genetics, Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (i) Myriad’s product, GeneSight, lacked evidence or information sufficient to support the tests in their current form, including their purported benefits; (ii) the U.S. Food and Drug Administration (“FDA”) had requested changes to GeneSight and questioned the validity of the test’s purported benefits; (iii) Myriad had been in ongoing discussions with the FDA regarding the FDA’s requested changes to GeneSight; (iv) Myriad’s acquisition of Counsyl-and thereby, Foresight-caused the Company to incur the risk of suffering from lower reimbursement for its expanded carrier screening tests, which had the potential to, and actually did, materialize into a material negative impact on the Company’s revenue; and (v) as a result, the Company’s public statements were materially false and misleading at all relevant times.
Learn about your recoverable losses in MYGN: http://www.kleinstocklaw.com/pslra-1/myriad-genetics-inc-loss-submission-form?id=3909&from=1.
Uber Technologies, Inc. (NYSE: UBER)
Class Period: on behalf of all persons and entities other than Defendants who purchased or otherwise acquired Uber securities pursuant and/or traceable to Uber’s registration statement issued in connection with Uber’s May 10, 2019 initial public stock offering.
Lead Plaintiff Deadline: December 3, 2019
The lawsuit alleges that throughout the class period, Uber Technologies, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) at the time of the initial public offering, Uber was rapidly increasing subsidies for customer’s rides and meals in a bid for market share, which caused the Company’s sales and marketing expenses to swell; and (2) Defendants were cutting (or planned to cut) costs in key areas that undermined the Company’s central growth opportunities.
Learn about your recoverable losses in UBER: http://www.kleinstocklaw.com/pslra-1/uber-technologies-inc-loss-submission-form?id=3909&from=1.
Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. If you suffered a loss during the class period and wish to obtain additional information, please contact J. Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.
J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: The Klein Law Firm
SOURCE: The Klein Law Firm
View source version on accesswire.com: